Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04246489 · ClinicalTrials.gov registry record · Phase 2
Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer
A Phase 2 study, sponsored by EMD Serono Research & Development Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 146
- Enrollment target
NCT04246489 is a Phase 2 study that has completed, run by EMD Serono Research & Development Institute. The registered enrollment target is 146 participants.
The verdict
NCT04246489, a Phase 2 study, has completed, sponsored by EMD Serono Research & Development Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 146 participants
- Enrollment target
Study Summary
The main purpose of this study was to evaluate clinical efficacy and safety of bintrafusp alfa in participants with advanced, unresectable cervical cancer with disease progression during or after platinum-containing chemotherapy.
Interventions
- DRUG Bintrafusp alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2020-03-30 |
| Est. Completion | 2022-12-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04246489
The ClinicalTrials.gov registry entry for NCT04246489 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 146 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bintrafusp alfa is the first listed.
NCT04246489 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04246489 about?
NCT04246489 is a clinical study titled "Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer". The main purpose of this study was to evaluate clinical efficacy and safety of bintrafusp alfa in participants with advanced, unresectable cervical cancer with disease progression during or after platinum-containing chemotherapy.
What is the current status of trial NCT04246489?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 146 participants. The study started on 2020-03-30. Estimated completion is 2022-12-14.
What interventions are being tested in trial NCT04246489?
The interventions under investigation include: Bintrafusp alfa (DRUG).
Who is sponsoring clinical trial NCT04246489?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.